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 Activation of Rho family small G proteins is thought to be a critical event in 
breast cancer development and metastatic progression.  Rho protein activation is 
stimulated by a family of enzymes known as guanine nucleotide exchange factors 
(Rho GEFs).  The neuroepithelioma transforming gene 1 (Net1) is a Rho GEF specific 
for the RhoA subfamily that is overexpressed in primary breast tumors and breast 
cancer cell lines.  Net1 isoform expression is also required for migration and invasion 
of breast cancer cells in vitro.  These data indicate that Net1 may be a critical regulator 
of metastatic progression in breast cancer.  Net1 activity is negatively regulated by 
sequestration in the nucleus, and relocalization of Net1 outside the nucleus is required 
to stimulate RhoA activation, actin cytoskeletal reorganization, and oncogenic 
transformation.  However, regulatory mechanisms controlling the extranuclear 
localization of Net1 have not been identified.  In this study, we have addressed the 
regulation of Net1A isoform localization by Rac1.  Specifically, co-expression of 
constitutively active Rac1 with Net1A stimulates the relocalization of Net1A from the 
nucleus to the plasma membrane in breast cancer cells, and results in Net1A 
activation.  Importantly, Net1A localization is also driven by endogenous Rac1 activity.  
Net1A relocalizes outside the nucleus in cells spreading on collagen, and when 
endogenous Rac1 expression was silenced by siRNA, Net1A remained nuclear in 
vi 
spreading cells.  These data indicate that Rac1 controls the localization of the Net1A 
isoform and suggests a physiological role for Net1A in breast cancer cell adhesion and 
motility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
TABLE OF CONTENTS 
Approval Signatures .………………………………………………………………………. i 
Title Page …………………………………………………………………………………….. ii 
Dedication …………………………………………………………………………………... iii 
Acknowledgements ……………………………………………………………………….. iv 
Abstract ……………………………………………………………………………………… v 
Table of Contents …………………………………………………………………………. vii 
List of Illustrations ………………………………………………………………………… ix 
CHAPTER 1:  INTRODUCTION …………………………………………………………… 1 
Genes commonly associated with Breast Cancer Initiation and Progression ………… 1 
Rho GTPases and Cancer ………………………………………………………………….. 4 
Regulation of Rho GEF activity …………………………………………………………….. 7 
The Rho GEF Net1 ………………………………………………………………………….. 9 
Net1 and DNA damage ……………………………………………………………………. 11 
Net1 mediated signaling through RhoA …………………………………………………. 12 
Regulation of Net1 activity ………………………………………………………………… 13 
Ran dependent Nuclear Import and Export ……………………………………………... 14 
Cellular Adherence to Extracellular Matrices and Cell Spreading ……………………. 15 
Constitutive activation of Rac1 stimulates Net1A extranuclear localization …………. 17 
CHAPTER 2:  MATERIALS AND METHODS ………………………………………….. 21 
Antibodies and cDNA constructs …………………………………………………………. 21 
Cell culture and transfection ………………………………………………………………. 21 
Recombinant protein expression …………………………………………………………. 22 
Net1 activity pulldowns …………………………………………………………………….. 23 
Rac1 activity assays ……………………………………………………………………….. 24 
viii 
Cell spreading assays ……………………………………………………………………... 25 
Immunofluorescence microscopy ………………………………………………………… 25 
CHAPTER 3:  RESULTS …………………………………………………………………. 26 
Constitutive activation of Rac1 stimulates Net1A activity ……………………………… 26 
Endogenous Rac1 controls Net1A localization …………………………………………. 28 
Spreading on collagen IV stimulates Rac1 activity and Net1A relocalization ……….. 29 
Rac1 controls Net1A relocalization during cell spreading ……………………………... 33 
CHAPTER 4:  DISCUSSION ……………………………………………………………... 36 
CHAPTER 5:  CONCLUSIONS ………………………………………………………….. 41 
References …………………………………………………………………………………. 43 
Vita …………………………………………………………………………………………... 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
List of Illustrations 
Figure 1.  Rho GTPase activation cycle ………………………………………………….. 5 
Figure 2.  Net1 proteins …………………………………………………………………… 10 
Figure 3.  Co-expression of V12Rac1 relocalizes Net1A outside the nucleus ………. 18 
Figure 4.  Co-expression of V12Rac1 stimulates Net1A activation …………………… 27 
Figure 5.  Endogenous Rac1 controls extranuclear localization of Net1A ………….. 29 
Figure 6.  Replating MCF7 cells on collagen strongly activates endogenous Rac1 .. 31 
Figure 7.  Relocalization of Net1A in cells spreading on collagen IV ………………... 33 
Figure 8.  Net1A relocalization during cell spreading requires Rac1 expression …... 35 
1 
CHAPTER 1:  INTRODUCTION 
Genes commonly associated with Breast Cancer Initiation and Progression  
 Breast cancer is the most widespread malignancy specific to women in the 
developed world and is the second leading cause of death, with approximately half a 
million fatalities worldwide per year (1, 2).  This high death rate continues despite 
improvements in diagnostics and treatments.  Breast cancer is a heterogeneous 
collection of diseases with diverse pathological factors, including aberrant hormone 
and growth factor regulation, genetic variations in key oncogenes and tumor 
suppressors, and altered cell-cell and cell-matrix adhesion.  Metastatic progression is 
the cause of death in breast cancer, yet our understanding of the mechanisms 
controlling metastasis is not fully understood.   
 Heightened activity or expression of particular extracellular ligand receptors, 
including the hormone receptors (HR) estrogen receptor (ER) and progesterone 
receptor (PR), and the epidermal growth factor receptor (EGFR) 2 (HER2/Neu), is 
recognized as a critical factor contributing to disease progression in human breast 
cancer.  In fact, HR over-expression occurs in 70% of breast tumors, while HER2 
positive (+) breast tumors can be detected in approximately 30% of patients (3-5).  
HR+ tumors are often more treatable and less aggressive compared to HR negative (-) 
tumors, which tend to exhibit greater metastatic spread and are not receptive to 
endocrine therapy (5).   
Estrogen is important in the development of reproductive tissues in women and 
for multiple physiological functions in adults.  For example, binding of ligand induces 
the ER to interact with estrogen response elements (ERE) in the promoters of 
estrogen responsive genes, and also recruits transcriptional co-activators to promote 
the transcription of these genes.  ER activation also elicits non-genomic activation of 
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multiple signaling cascades, including the PKC, PKA, PI3K-Akt, and MAPK pathways 
(6, 7).  In cancerous ER+ tissues, estrogen promotes vascular endothelial growth 
factor (VEGF) and Transforming Growth Factor-β (TGF-β) secretion to stimulate 
carcinoma cell growth (6).  Endocrine therapy approaches for ER+ tumors include ER 
antagonists or selective estrogen receptor modulators (SERM) (2).  Tamoxifen is an 
ER antagonist that prevents the binding of estrogen to the ER, while aromatase 
inhibitors, such as Anastrozole, are SERMs that inhibit estrogen biosynthesis (2, 8).   
HER2 is a proto-oncogene with relatively low expression in normal breast tissue 
that is inversely proportional to the expression levels of ER, and is down-regulated by 
estrogen (5).  Binding of ligand to the HER2 causes it to dimerize with other EGFR 
family members, stimulating the MAPK, PI3K and PLC pathways (5, 9).  Over-
expression of HER2 in breast cancer correlates with an up-regulation of cyclin D1 
expression, which is an essential regulator of G1/S phase progression in the cell cycle, 
promoting tumor cell growth (10).  HER2+ tumors are generally sensitive to therapy 
using HER2-specific monoclonal antibodies, such as trastuzumab (5, 9, 10).  However, 
recurrence of breast cancer in patients receiving anti-HER2 therapy indicates that 
additional treatment approaches are needed.   
 Tumor suppressor genes that have been shown to be mutated in breast cancer 
and to contribute to breast cancer risk include the BRCA1/2 and TP53 tumor 
suppressor genes (11).  For example, inheritance of mutations in the BRCA1 or 
BRCA2 genes, which are responsible for DNA repair, significantly increases the risk of 
breast cancer (3, 12).  BRCA1 mutation-containing cancers typically lack ER, PR, and 
HER2 expression, and occur in only 5% to 10% of breast cancer cases.  However, 
about 30% of sporadic breast cancers exhibit reduced BRCA1 mRNA and protein 
expression (3, 13).  On the other hand, TP53 gene mutations are the most common 
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genetic alteration in human cancer and have been detected in human breast tumors 
(14).  The TP53 gene regulates essential cellular processes such as DNA repair and 
apoptosis.  Thus, p53 mutations typically allow a cancer cells to evade death in the 
presence of genetic imbalances or apoptotic stimuli (11).   
Another hallmark of breast cancer is the process of epithelial to mesenchymal 
transition (EMT), which involves the loss of cell polarity, cell-cell and cell-matrix 
adhesion, and an increase in cell motility (15, 16).  Precursor tumor cells undergo EMT 
through aberrant regulation of adherens junctions (AJ), tight junctions (TJ), and 
integrin-extracellular matrix (ECM) adhesion.  Studies have shown that dysregulation 
of AJs, such as the loss of E-cadherin expression, and TJs, such as dysregulation 
within the Partitioning defective (Par) complex, lead to breast cancer tumorigenesis in 
cells and in animal models which incorporate much of the diversity of human breast 
cancer (17-20).   
Abnormal regulation of cell-matrix adhesions also promotes tumor invasive 
potential.  Integrins constitute the major transmembrane receptor that binds to the 
ECM and have been implicated in tumor cell survival, invasion, migration, and 
anchorage at metastasis sites (21).  For example, the alpha6-beta4 (α6β4) and α6β1 
integrins promote tumor cell survival and motility, and the α1 and α2 integrins have 
been implicated in controlling the expression of the matrix metalloproteinase (MMP) 
MMP-3/stromelysin-1, promoting tumor cell invasion (21-24).  The α3β1 and αvβ1 
integrin dimers are also associated with tumor cell migration and invasion due to 
MMP-9 production (25, 26).  However, the mechanisms underlying the dysregulation 
of cell adhesion in breast cancer are not fully understood. 
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Rho GTPases and Cancer 
 The Rho family of small GTPases contains 23 members and is part of the Ras 
superfamily of monomeric GTPases.  Amongst the Rho GTPases, RhoA, Rac1, and 
Cdc42 are the most extensively characterized (27).  Rho family small G proteins 
regulate many critical processes of cell physiology, including actin cytoskeletal 
organization, cell cycle progression, cell motility, gene expression, vesicle trafficking, 
cell polarity, proliferation, cell-cell and cell-matrix adhesion (28-31).  Rho proteins act 
as molecular switches, cycling between inactive, GDP-bound, and active, GTP-bound 
states, and upon activation, Rho proteins interact with effector proteins to stimulate 
multiple cell signaling pathways (Figure 1) (27, 32).  Rho protein activation is mediated 
by guanine nucleotide exchange factors (GEFs) that catalyze GDP release to facilitate 
GTP loading (33).  GTPase activating proteins (GAPs) stimulate the intrinsic GTPase 
activity of Rho proteins to inactivate their function (34).  Guanine nucleotide 
dissociation inhibitors (GDIs) sequester GDP-bound Rho proteins into the cytoplasm 
(35).  
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Figure 1.  Rho GTPase activation cycle.  Rho GTPases cycle between inactive 
(GDP-bound) and active (GTP-bound) states.  Intrinsic Rho GTPase activity is 
stimulated by Rho GAPs, down-regulating Rho GTPases.  GDP-bound Rho 
GTPases are sequestered in the cytoplasm by GDIs.  Rho GEFs catalyze GTP 
binding by Rho GTPases, stimulating their activation.  Active Rho proteins 
interact with downstream effector (E) proteins to control many cellular 
processes, including cytoskeletal organization, cell cycle progression, gene 
expression, vesicle trafficking, cell polarity, proliferation, cell-cell, and cell-matrix 
adhesion. 
 
 
 
Aberrant signaling, activation, or expression of Rho proteins can lead to 
increased proliferation, EMT, and transformation, and are critical for cancer cell motility 
and invasion (36-39).  Overexpression of Rho proteins in human cancer seems to be a 
frequent occurrence.  For example, over-expression of RhoA and RhoC has been 
observed in multiple human cancers, including breast cancer (40-43).  Furthermore, 
because both RhoA and RhoC stimulate cell motility, enhanced RhoA or RhoC 
expression in breast tumors suggests that they may promote metastatic progression 
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(44).  However, the overexpressed Rho proteins are invariably wild type, meaning Rho 
GEFs and Rho GAPs still control their activation state.   
There are more than 70 Rho GAPs and 70 Rho GEFs encoded by the human 
genome, which allows for pathway specific regulation of Rho activity (45, 46).  Two 
distinct families of Rho GEFs up-regulate Rho GTPase activity, the canonical Dbl 
(diffuse B-cell lymphoma) family and the non-conventional DOCK (Dedicator of 
cytokinesis) or CZH (CDM [Ced-5, Dock180 and Myoblast city]-Zizimin homology) 
family of Rho GEFs.  DOCK family Rho GEFs activate Rac and Cdc42 GTPases to 
control cell migration, morphogenesis, and phagocytosis, and contain conserved 
DHR2 (DOCK homology region 2) catalytic domains and conserved DHR1 domains 
(47).  Dbl family Rho GEFs contain conserved, tandem Dbl homology (DH) and 
Pleckstrin homology (PH) domains (33, 47-49).  The catalytic activity of Rho GEFs 
resides in the DH domain, while the PH domain stabilizes the DH domain-Rho protein 
interaction and has been observed to control binding of Rho GEFs such as Lbc 
(Lymphoid blast crisis), Lfc (Lbc’s first cousin), and Dbs (Dbl’s big sister) to 
phosphatidyl-inositol lipids (48, 50-53).  Many canonical Rho GEFs, such as Dbl, Vav 
(sixth letter of the Hebrew alphabet), Neuroepithelioma Transforming Gene 1 (Net1), 
and Lfc, were first identified as oncogenes in NIH3T3 cell transformation assays.  In all 
cases their transforming activity was dependent on their ability to stimulate Rho protein 
activation (49, 54-56).  In addition, over-expression of Rho GEFs such as T-cell 
lymphoma invasion and metastasis-inducing protein 1 (Tiam1), leukemia-associated 
Rho GEF (LARG), and Net1 has been observed in human tumors (57-59).  However, 
the requirement for particular Rho GEF activity in tumor development and progression 
has not been evaluated at length.   
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Regulation of Rho GEF activity 
Regulatory mechanisms controlling Rho GEF activity have only been 
extensively studied for a few proteins.  Almost all Rho GEFs display specificities for 
different Rho family small G proteins and can be regulated by post-translational 
modifications, such as phosphorylation, ubiquitylation, PDZ (PSD-95/Disc-large/ZO-1)-
domain protein interaction, and subcellular localization (33, 60-62).   
For example, Tiam1 catalyzes nucleotide exchange specifically for Rac1, while 
the Rho GEF XPLN is specific for RhoA and RhoB, but not RhoC (63, 64).  Moreover, 
Rho GEFs such as Vav, Dbl, FRG (FGD1 [faciogenital dysplasia gene product]-related 
Cdc42 GEF), Tiam1, and Epithelial cell transforming sequence 2 (Ect2) are positively 
regulated by phosphorylation (65-69).  Dbl activity is enhanced by tyrosine 
phosphorylation by the tyrosine kinase, activated Cdc42 kinase 1 ACK1 (67).  FRG is 
directly phosphorylated and activated by Src kinase, which underlies cell motility 
inhibition downstream of the endothelin A receptor (68).  GEF phosphorylation can 
also coincide with particular phases of the cell cycle, as indicated by Ect2 up-
regulation by phosphorylation during the G2/M phase of the cell cycle (70).  
Furthermore, phosphorylation can be accompanied by lipid binding, as observed when 
Vav is activated by binding to phosphoinositide 3, 4, 5-phosphate (PIP3) and by 
lymphocyte-specific protein tyrosine kinase (Lck)-mediated phosphorylation (65, 66, 
71).    In addition, phosphorylation can be induced by ligand stimulation.  Exposure to 
the agonist lysophosphatidic acid (LPA), or  increases in intracellular Ca2+, induce 
protein kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II 
phosphorylation of Tiam1, respectively, to increase its activity (69).   
Rho GTPase activity can also be down-regulated by ubiquitin-stimulated 
degradation of Rho GEFs by the proteasome (72).  For example, after mitosis, RhoA 
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activity is reduced by ubiquitin-mediated degradation of the Rho GEF Ect2 (73).  Dbl is 
another Rho GEF that is ubiquitylated by the E3 ligase, CHIP (carboxyl terminus of 
HSC70-interacting protein) to target it for proteasome degradation (74).  Additionally, 
the Cdc42 specific GEF, hPEM-2 (human homologue of the Ascidian protein Posterior 
End Mark-2), is ubiquitylated by the E3 ligase, Smurf1 in a Ca2+ independent manner, 
while Net1 has been found to be ubiquitylated following disengagement of E-cadherin  
(75, 76).   
In addition, about 40% of Rho GEFs have a PDZ binding motif (PBM) that is 
predicted to mediate interaction with PDZ domain containing proteins.  However, the 
PBM has only been shown to be functional for a few Rho GEFs (62).  Proteins 
containing PDZ domains often act as scaffolds to promote specific cellular localization 
of signaling molecules and increased protein-protein interactions.  PDZ-domain 
proteins also provide a mechanism for regulating Rho GEF subcellular targeting and 
activation.  For example, the neuronal Rho GEF Kalirin-7 interacts with postsynaptic 
density protein 95 (PSD-95), targeting Kalirin-7 to the PSD to regulate dendritic 
morphogenesis through Rac1 signaling (77).  Two other PDZ-domain proteins, 
Scribble and Shank, form complexes with the Rho GEF Pak-interacting exchange 
factor-beta (β-PIX) and localize β-PIX to pre-synaptic sites in neurons to promote 
exocytosis and dendritic protrusions, respectively (78, 79).  Furthermore, the PDZ-
domain protein, synectin, binds to and recruits the RhoA-specific GEF, Syntaxin 1A 
(Syx1), to the plasma membrane, promoting local RhoA activation (80).  Finally, Net1 
(Net1A isoform) interaction with the PDZ-domain containing protein, Dlg1, prevents 
proteasome mediated degradation of Net1A to allow for maximal stimulation of RhoA 
activity (76, 81). 
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Lastly, subcellular localization is an important mechanism for controlling Rho 
GEF activity. For example, inactive Rho GTPases and most Rho GEFs are primarily 
localized in the cytosol.  Upon activation, both the Rho proteins and their respective 
GEFs re-localize to the plasma membrane.  However, two Rho GEFs, Ect2 and Net1, 
diverge from this regulatory paradigm and are localized to the nucleus at a steady 
state (70, 82).  This represents a mechanism to downregulate their activity, as 
truncation of their respective N-termini relocalizes Ect2 and Net1 outside the nucleus 
to potentiate RhoA and RhoB activation (70, 82).   
 
The Rho GEF Net1 
 Net1 is a Rho GEF specific for the RhoA subfamily (33, 60).  Net1 was originally 
cloned from a human neuroepithelioma cDNA library in a screen for novel transforming 
genes using a focus formation assay in NIH3T3 fibroblasts (83).  In this screen, a non-
naturally occurring 5’ truncated form of Net1 (lacking the first 145 amino acids) was 
found to have transforming properties.  NIH3T3 cells expressing this truncated form of 
Net1 exhibited increased proliferation, loss of contact inhibition, and anchorage 
independent growth in vitro, and were tumorigenic when injected into nude mice (83).  
The NET1 gene encodes a protein of 595 amino acids with tandem DH domain and 
PH domains, with 155 amino acid amino-terminal and 93 amino acid carboxyl-terminal 
regulatory domains (Figure 2) (60, 61, 83, 84).  The presence of multiple nuclear 
localization signal (NLS) sequences in the N-terminal regulatory domain of Net1 
targets it to the nucleus at steady state (61).  The C-terminus of Net1 also contains a 
Type I PBM (X-S/T-X-V-COOH [X being any amino acid]) allowing for interaction with 
the PDZ domain containing proteins Dlg1 (Discs large gene 1) and Magi-1 
(Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1) 
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(81, 85).  Interaction with Dlg1 protects the Net1A isoform from proteasome mediated 
degradation (81, 86).   
 
Figure 2.  Net1 proteins.  (A)  Net1 is 595 amino acids in length.  Net1 contains NLS 
sequences within the N-terminus, indicated by yellow boxes, followed by 
tandem DH and PH domains, illustrated by the red and blue boxes, 
respectively.  The PBM sequence, ETLV, lies at the carboxyl terminal end of 
Net1.  The splice variant, Net1A, is identical to Net1 except in the N-terminus.  
Specifically, Net1A lacks the first 85 amino acids of Net1 and contains a distinct 
31 amino acid sequence, as denoted by the green box.  Net1ΔN lacks the first 
121 amino acids of Net1.  (B)  Amino acid sequence of the NLS sequences in 
Net1 and Net1A. 
 
 
 
There are two Net1 isoforms that exist in most cells, Net1 and the splice variant 
Net1A.  Expression of Net1 isoforms is controlled by alternative promoters within the 
NET1 gene, which are inversely regulated by estradiol (59).  The difference between 
the primary amino acid sequences of Net1 and Net1A lies within their unique amino-
termini.  The amino-terminus of Net1A lacks the first 85 amino acids of full length Net1 
and has its own unique 31 amino acids (81).  Net1 contains 4 putative NLS 
sequences, while Net1A only contains the NLS sequences corresponding to NLS3 and 
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NLS4 in Net1 (Figure 2).  Net1 also contains a putative nuclear export signal (NES) 
within the PH domain, however, mutation of the NES in Net1 did not affect 
chromosomal region maintenance protein 1 (CRM1)-dependent export (61).  Net1 NLS 
sequences allow for nuclear import of Net1 isoforms, and truncation of the N-terminal 
regulatory domain results in the oncogenic form known as Net1ΔN.  Net1N mainly 
localizes outside the nucleus to constitutively stimulate RhoA activity and actin stress 
fiber formation, indicating that localization of Net1 in the nucleus is a form of negative 
regulation (60, 61, 87).  However, signaling mechanisms controlling the nuclear import 
or export of Net1 isoforms have yet to be identified.   
Both Net1 isoforms are overexpressed in various cancers, including gastric, 
breast, ovarian, cervical, and pancreatic cancers (59, 88, 89).  Moreover, Net1 isoform 
expression is necessary for migration and invasion of MDA-MB-231 breast cancer 
cells and gastric adenocarcinoma cells (AGS) in vitro, suggesting that Net1 may be a 
critical regulator of metastatic progression in cancer (88).  Furthermore, Net1 and 
integrin alpha6beta4 (α6β4) co-expression in primary tumors of lymph node-positive 
breast cancer patients and Net1 overexpression in ER positive (ER+) breast tumors 
selects for high risk distant metastasis (59, 89).  Thus, understanding regulatory 
mechanisms controlling Net1 activity may be important for discerning breast cancer 
metastasis. 
 
Net1 and DNA damage 
Net1 localizes to the nucleus, sequestered away from RhoA at the plasma 
membrane.  This is thought to leave Net1 biologically inert.  However, Net1-dependent 
RhoA localization and activation in the nucleus has been observed in response to DNA 
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damage (90, 91).  This indicates that Net1 may have additional, non-classical nuclear 
functions that are not well appreciated.  However, the exact role of Net1 in DNA 
damage responses is still unclear.  For example, it has been shown that Net1 
expression is required for activation of the p38 Mitogen Activated Protein Kinase 
(MAPK)-MAPKAP2 signaling pathway after exposure to genotoxic agents such as 
ionizing radiation (IR), which promotes survival in HeLa cells (91, 92).  On the other 
hand, in MCF7 breast cancer cells IR-stimulated DNA damage causes Net1- and Ect2-
dependent RhoB activation, which inhibits cell survival (93).  Thus, the role of Net1 in 
DNA damage signaling may be cell type specific. 
 
Net1 mediated signaling through RhoA 
RhoA activation induces various downstream signal transduction pathways that 
control actin cytoskeletal rearrangement, transformation, adhesion, and gene 
expression.  For example, TGF-β stimulates Smad activity, which enhances Net1 
expression, leading to increased Rho activity and actin stress fiber formation (84, 94).  
Net1 dependent activation of downstream stress fiber formation is down-regulated by 
co-expression with the scaffold protein Connector Enhancer of Kinase Suppressor of 
Ras 1 (CNK1) (87, 95).  Importantly, CNK1 co-expression causes Net1 to stimulate 
RhoA-dependent SAPK/JNK pathway activation.  These findings indicate that 
signaling downstream of Net1 is regulated by associated proteins (60, 95).  Net1 also 
has the ability to induce SAPK/JNK activation independently of the generation of 
titratable GTP-bound RhoA (60).  Moreover, the PBM of Net1 is not required for RhoA 
dependent cytoskeletal effects, but is necessary for cellular transformation (87).  On 
the other hand, Net1ΔN interaction with Dlg1 reduces the transformation potential of 
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oncogenic Net1 (81).  Altogether, this indicates that Net1 activity is differentially 
regulated towards RhoA and transformation. 
 
Regulation of Net1 activity 
Net1 activity is regulated by phosphorylation, ubiquitylation, and subcellular 
localization (61, 76, 81, 87, 96).  Additionally, TGF-β inhibits Net1 expression by the 
microRNA miR-24 (94).  The exchange activity of Net1 and its ability to stimulate 
stress fiber formation is reduced by phosphorylation of serines 152 and 153 (S152, 
S153) by p21 Activated Kinase 1 (PAK1) in response to Rac1 activation (96).  
Disruption of E-cadherin engagement leads to decreased Net1A and Dlg1 interaction 
and subsequent Net1A ubiquitylation, thus indicating enhancement of Net1A stability 
in response to cell-cell contact (76).  Increased Net1A stability correlates with 
increased interaction with Dlg1 and relocalization of Net1A/Dlg1 complexes to the 
subnuclear structures, the promyelocytic leukemia protein (PML) bodies (76, 81).  This 
indicates Net1A association with Dlg1 which protects Net1A from ubiquitin-mediated 
degradation and this interaction is regulated by cell-cell contact (76).  Lastly, down-
regulation of Net1 activity also occurs through nuclear sequestration (61, 87).  Deletion 
mutants of Net1, containing various NLS aberrations or N-terminus abnormalities, 
exhibit cytoplasmic localization, indicative that the N-terminus of Net1 regulates 
subcellular localization through these NLS sequences.  Extranuclear localization of 
Net1 isoforms is required for RhoA activation and stress fiber formation.  However, 
stimuli that cause increased nuclear export or decreased nuclear import of Net1 
isoforms, thereby relocalizing Net1 outside the nucleus, have not been described. 
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Ran dependent Nuclear Import and Export 
Nuclear import and export are typically regulated by families of binding proteins 
known as importins and exportins, which function as chaperones to mediate transit 
through the nuclear pore.  Importins are classified as karyopherins (97).  Karyopherins 
have two subunits, importin α and importin β, of which there are six importin α subunits 
in humans, namely KPNA1, 2, 3, 4, 5, and 6.  Importin α binds to the NLS of a protein 
to be imported into the nucleus, while importin β binds to importin α and mediates 
docking to the nuclear pore complex (NPC) and translocation through the pore.  The 
importin β subunit can also bind to a NLS protein without the aid of an importin α 
subunit.  The importin/NLS complex binds the GDP-bound Ras family GTPase, Ran 
(Ras-related nuclear protein).  Together, this complex moves through the nuclear pore 
by forming contacts with nucleoporins.  Once inside the nucleus, GDP-Ran interacts 
with chromatin bound RCC1 (a Ran GEF), which causes GTP binding.  GTP-bound 
Ran triggers a conformational change of importin β to catalyze release of the NLS 
containing protein from importin α (98, 99).  Cargo that needs to be exported outside 
the nucleus utilizes exportins.  There are seven exportins in humans, respectively 
named CRM1 (Chromosome region maintenance protein 1) (XPO1), CAS (Cellular 
Apoptosis Susceptibility Protein) (XPO2), XPO T (XPO3), XPO4, XPO5, XPO6, and 
XPO7.  Of these, CAS controls the nuclear export of importins after they shuttle cargo 
into the nucleus and XPOT mediates the nuclear export of tRNAs (98, 99).  A 
consensus NES has only been defined for CRM1.  Exportins bind to the NES of a 
protein to form a ternary complex with RanGTP.  Upon translocation through the 
nuclear pore, cytoplasmic RanGAP1 stimulates GTP hydrolysis by Ran, causing 
complex dissociation and the release of the exported cargo into the cytoplasm (98, 
99).   
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Cellular Adherence to Extracellular Matrices and Cell Spreading 
 Adhesion of cells to the ECM provides structural support for cells and is critical 
for tissue development and homeostasis.  ECM binding also mediates activation of 
multiple signaling pathways to regulate cellular behavior.  The ECM is comprised of an 
interlocking mesh of assorted fibrous proteins and proteoglycans, such as heparan 
sulfate, elastins, fibronectins, laminins, and collagens, of which collagen is the most 
abundant (100-102).  Cells bind to the ECM through different cell surface receptors, 
including syndecans and integrins.  The major receptors for cell adhesion to the ECM 
are integrins (103).  Integrins are heterodimeric transmembrane receptors composed 
of single  and  chains. There are 18 α and 8 β subunits in mammals, which 
assemble into 24 distinct integrin complexes, allowing for specificity in ECM 
component binding and intracellular signaling (103).  For example, while integrins 
α1β1 and α2β1 both bind collagen I and IV, α2β1 preferentially interacts with collagen I 
while α1β1 has a higher affinity for collagen IV (104-106).  Integrins behave as 
bidirectional signal transducers, transmitting signals from the inside of the cell to the 
outside through cytoplasmic binding to cytoskeletal adaptor proteins, or from the ECM 
to the inside of the cell through extracellular ligand binding (103).   
 Following initial adherence to an ECM, cells begin to flatten and spread out.  
During this process, signaling events are triggered by integrin engagement.  Prior to 
ECM binding, the protein Talin binds to the β subunit of the integrin dimer, inducing a 
conformational change in an integrin receptor that allows for binding to the ECM.  
Following binding of the integrin heterodimer to the ECM the focal adhesion kinase 
(FAK) is recruited.  Clustering of multiple ECM-bound integrins allows for the trans-
phosphorylation of FAK molecules on tyrosine 397, which creates a binding site for the 
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tyrosine kinase Src (107, 108).  Src binding leads to further tyrosine phosphorylation of 
FAK as well as increased Src phosphorylation, maximizing the kinase activity of the 
FAK-Src complex (109).  This FAK-Src complex recruits and activates scaffolding and 
adaptor proteins, such as p130Cas and paxillin.  These proteins recruit additional 
signaling molecules to initiate cell signaling.  Among these events, activation of the 
Rho family proteins Rac1 and Cdc42 is crucial.  Their activation is mediated by binding 
to the Rac1 and Cdc42 exchange factors, the unconventional GEF Dock180-
engulfment and motility 1 (ELMO1) complex and β-PIX, which stimulate Rac1 and 
Cdc42 activation to promote membrane protrusion (110-112).  Once activated, Cdc42 
and Rac1 promote the extension of filopodia and lamellipodia that allow for early cell 
spreading. Rac1 stimulation also induces reactive oxygen species production, which 
inhibits tyrosine phosphatase activity toward p190RhoGAP, thereby activating 
p190RhoGAP and inhibiting RhoA activity.  This diminishes actomyosin contractility in 
the spreading edge of the cell (113-116).   
In the later stages of spreading, 60 to 90 minutes following adhesion, Rac1 and 
Cdc42 activities decrease and RhoA activity steadily increases, driving maturation of 
focal complexes (FC) to focal adhesions (FA), promoting the formation of actin stress 
fibers.  This provides cellular anchorage to the ECM and enhances actomyosin 
contraction (113, 114, 117, 118).  RhoA activation also stimulates Rho-associated 
protein kinase (ROCK)-mediated phosphorylation of the Rac1 GAP FilGAP, thereby 
down-regulating Rac1 activity (117, 118).  In fibroblasts the increase in RhoA activity 
at later stages of cell spreading has been shown to require the actions of the Rho 
GEFs LARG, p115RhoGEF (Lsc), and p190RhoGEF (119, 120).  However it is not 
clear how the activity of these Rho GEFs are coordinated during cell spreading, nor is 
it known why multiple RhoA directed GEFs are required for efficient spreading.  Also, 
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most of these studies have been conducted in mouse fibroblasts.  It is possible that 
different Rho GEFs may be operative in human breast cancer cells. 
 
Constitutive activation of Rac1 stimulates Net1A extranuclear localization 
 Previous work in the Frost lab was directed at screening upstream regulators 
and downstream effectors of Rho proteins to identify factors that would cause 
relocalization of Net1 isoforms from the nucleus. From these efforts, the lab found that 
co-expression of constitutively active Rac1 (V12Rac1) caused a dramatic re-
localization of Net1A outside the nucleus in transfected MCF7 breast cancer cells.  As 
shown in Figures 3A and 3B, when transfected alone, Net1 and Net1A localized 
outside of the nucleus in approximately 15% and 25% of transfected cells, respectively 
(61, 87, 96).  However, co-expression of V12Rac1 robustly increased the percent of 
transfected cells with extranuclear Net1A to more than 80% of cells.  This considerable 
effect, however, was not observed when V12Rac1 was co-expressed with Net1, 
suggesting that the localization of Net1 and Net1A are regulated differently.  
Furthermore, using subcellular fractionation followed by Western blotting, the 
localization of HA-tagged Net1A in the membrane fraction was significantly increased 
by co-expression of Myc-tagged V12Rac1, indicating that Net1A was re-localized to the 
membrane (Figure 3C). 
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Figure 3.  Co-expression of V12Rac1 relocalizes Net1A outside the nucleus.  (A)  
MCF7 cells were transfected with HA-Net1 or HA-Net1A, plus control vector or 
Myc-V12Rac1, and processed for immunofluorescence by using anti-HA 
antibodies (green), anti-Myc antibodies (red), and DAPI (stains DNA, blue).  A 
representative panel for each transfection is shown.  The constructs used for 
each condition are indicated to the left of each panel.  (B)  Quantification of 
extranuclear Net1 isoform localization.  At least 100 cells were counted for each 
condition.  Significance was estimated by Student’s t test for non-paired values.  
Error bars represent standard error of the mean.  * = P <0.002.  (C)  Cells were 
transfected with HA-Net1A alone or with Myc-V12Rac1 and processed for 
subcellular fractionation.  Proteins within each fraction were analyzed by 
Western blotting using the indicated antibodies.  Results of a representative 
experiment are shown (Frost Lab, data not published).   
 
 
 
Since V12Rac1 co-expression relocalized Net1A outside the nucleus, the Frost 
Lab also tested whether the related Rho GTPase Cdc42 also caused Net1A 
relocalization in transfected MCF7 cells.  In these experiments, Net1A localization was 
tested only one day after transfection, as expression of constitutively active Cdc42 
(V12Cdc42) was toxic to MCF7 cells after longer periods of time (data not shown).  In 
these assays, it was found that co-expression of V12Rac1 caused extranuclear 
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localization of Net1A in approximately 60% of the cells while V12Cdc42 only caused 
30% of the cells to exhibit extranuclear Net1A (data not shown), suggesting that 
V12Rac1 is more effective than V12Cdc42 for stimulating Net1A relocalization outside 
the nucleus.   
The Frost Lab also determined what aspects of Net1A function were required 
for Rac1-stimulated relocalization.  For these assays the following Net1A mutants 
were tested: catalytically inactive Net1A (L267E, L/E); the PH domain mutant (W438L, 
W/L) (60), and the deletion mutant Net1A 1-307, which lacks the PH domain and the 
C-terminal regulatory domain (Figure 2).  Immunofluorescence analysis showed that 
each Net1A mutant efficiently relocalized outside the nucleus when co-expressed with 
V12Rac1.  Co-expression of wild type Net1A, Net1A L/E, and Net1A W/L with V12Rac1 
caused approximately 70% of the cells to contain extranuclear Net1A.  Rac1 was 
slightly less efficient at causing re-localization of Net1A 1-307, with only 60% of the 
cells exhibiting extranuclear Net1A localization (data not shown).  Taken together, 
these results demonstrate that the catalytic activity, potential phosphatidyl-inositol 
binding ability, and C-terminal sequences within Net1A are not necessary for 
stimulation of its relocalization outside the nucleus by V12Rac1.    
Extranuclear localization of Net1 is required for RhoA activation, actin 
cytoskeletal reorganization, and oncogenic transformation.  However, regulatory 
mechanisms controlling the import or export of Net1 have not been identified.  It has 
been determined that the relocalization of Net1A from the nucleus to the plasma 
membrane in breast cancer cells is regulated downstream of constitutively activation of 
Rac1.  Through the current study, we established that Rac1 expression and activation 
are necessary for Net1A relocalization during cell spreading.  These results suggest 
that Net1 isoforms are regulated differently and that Rac1-mediated relocalization of 
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Net1A may be a significant determinant of the ability of cells to adhere to an ECM and 
for cell motility.  
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CHAPTER 2:  MATERIALS AND METHODS 
Antibodies and cDNA constructs 
The following antibodies were used:  anti-Rac1, anti-Cdc42, and anti-paxillin 
(BD Biosciences); anti-GAPDH, anti-glutathione S-transferase (GST), anti-Net1, anti-
HA, anti-SOD1, and anti-Na+/K+ ATPase (Santa Cruz); anti-RhoA (Cytoskeleton); anti-
H3 and anti-phosphoFAK (Y397) (Cell Signaling); anti-Myc epitope (AbCam); and anti-
-tubulin (Sigma).  Primary antibodies used for Western blotting were detected with 
horseradish peroxidase-conjugated secondary antibodies (Kirkegaard & Perry 
Laboratories) via enhanced chemiluminescence (ECL).    For immunofluorescence 
microscopy, Cy2- and Cy3- conjugated anti-mouse and anti-rabbit secondary 
antibodies were from Jackson ImmunoResearch.  TRITC-phalloidin and 4’, 6-
diamidino-2-phenylindole (DAPI) were from Sigma.  Alexa 647-phalloidin was from 
Invitrogen.  Wild type and constitutively active V12Rac1 and V12Cdc42 were in 
pCMV5M, as described (96).  Mouse Net1, Net1A and their respective mutants were in 
pEFHA (87).  DNA sequencing was used to verify all constructs.  
 
Cell culture and transfection 
MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma) and antibiotics 
(100 units/mL penicillin-streptomycin) (HyClone).  MCF7 cells were transfected with 
cDNA expression vectors using Lipofectamine/Plus (Invitrogen) following the 
manufacturer’s instructions.  Cells were assayed 48 h after transfection. 
 Small interfering RNAs (siRNA) against human Rac1 were from Sigma.  Rac1 
siRNA sequences were as follows: Rac1-1 sense, 5’-
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AAGGAGAUUGGUGCUGUAAAAUU-3’, and antisense, 5’-
UUUUACAGCACCAAUCUCCUU-3’; and Rac1-2 sense, 5’-
AACCUUUGUACGCUUUGCUCAUU-3’, and antisense, 5’-
UGAGCAAAGCGUACAAAGGUUUU-3’.  The RNA sequences, sense, 5’- 
GAUCAUACGUGCGAUCAGAUU-3’, and antisense, 5’-
UCUGAUCGCACGUAUGAUCUU-3’, was used as a non-targeting control (Sigma).  
MCF7 cells were transfected with siRNAs using the INTERFERin transfection reagent 
(Polyplus) according to manufacturer’s instructions.  Cells were assayed 96 h after 
transfection with Rac1 siRNA. 
 
Recombinant protein expression 
V17A-RhoA (RhoA(17A)) in pGEX-KG was created by PCR-mediated 
mutagenesis and verified by DNA sequencing.  GST- or GST-RhoA17A proteins were 
purified as previously described (121).  Briefly, BL21(DE3) E. coli transformed with 
pGEX-KG or pGEX-KG/RhoA(17A) were cultured to O.D.600 = 0.8 and GST protein 
expression was induced for 12 to 16 h at room temperature following the addition of 50 
M IPTG (isopropyl-β-D-thiogalactopyranoside).  Bacterial cells were collected by 
centrifugation (6,000 x g), lysed in buffer containing 20 mM HEPES pH 7.5, 150 mM 
NaCl, 5 mM MgCl2, 1% Triton X-100, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), and 10 g/ml each of aprotinin, leupeptin, and pepstatin A, and insoluble 
material was pelleted by centrifugation (20,000 x g, 30 minutes, 4°C). GST or GST-
RhoA17A in the soluble fraction was purified by incubation with glutathione-agarose 
beads (Sigma) for 1 h at 4°C, followed by two washes with lysis buffer and two washes 
with lysis buffer lacking Triton X-100 and protease inhibitors.  Protein purity was 
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assessed by Coomassie staining and concentrations were tested by BCA assay 
(Pierce).  Proteins were left attached to the beads and frozen in aliquots.   
 Rac1 activity was measured by pulldown assay using the p21-binding domain 
(PBD) of Pak1 cloned into pGEX-2T, a kind gift from Catherine Denicourt (UT-
Houston).  Prokaryotic expression of the pGEX-2T/PBD construct was performed as 
described (122).  Briefly, BL21(DE3) E. coli transformed with pGEX-2T/PBD were 
grown to O.D.600 = 0.8 and expression of the GST or GST-PBD fusion proteins in was 
induced with 400 M IPTG for 3 h at 30°C.  Bacterial cells were pelleted by 
centrifugation (6,000 x g) and re-suspended in buffer containing 50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg/ml 
lysozyme (Fisher), and 10 g/ml each of aprotinin, leupeptin, and pepstatin A.  After 
sonication, insoluble material was pelleted by centrifugation (12,000 x g, 10 min, 4°C), 
and soluble proteins were incubated with glutathione-agarose beads for 1 h at 4°C 
followed by three washes using buffer containing 50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 5 mM MgCl2, 1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin, 
leupeptin, and pepstatin A.  Protein purity was assessed by Coomassie staining and 
concentrations were tested by BCA assay.  Proteins were left attached to the beads 
and frozen in aliquots.   
 
Net1 activity pulldowns 
Active Net1 pulldown experiments were performed as described (121).  Briefly, 
cells were lysed in lysis buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
1% Triton X-100, 1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin, leupeptin, 
and pepstatin A), sonicated for 30 s, and clarified by centrifugation (13,000 x g, 5 min, 
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4°C).  Lysates concentrations were determined by BCA assay and equal amounts of 
lysate were mixed for 1 h at 4°C with 20 μg of GST or GST-RhoA17A beads.  Beads 
were pelleted by centrifugation and washed 3 x in lysis buffer, resuspended in 25 l 
sodium dodecyl sulfate (SDS) sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 
2% SDS, 0.02% bromophenol blue, and 10% glycerol), boiled for 5 min, and separated 
by SDS-polyacrylamide gel electrophoresis (PAGE).  Proteins were transferred to 
polyvinylidene fluoride (PVDF) membrane (GE, Millipore) and immunoblotted with the 
indicated antibodies.   
 
Rac1 activity assays  
 Active Rac1 pulldown experiments were performed as described (122).  Briefly, 
suspended and adherent cells were lysed in buffer containing 50 mM Tris-HCl pH 7.5, 
200 mM NaCl, 10 mM MgCl2, 1% NP-40, 5% glycerol, 1 mM PMSF, and 10 g/ml 
each of aprotinin, leupeptin, and pepstatin A and incubated on ice for 5 min.  Insoluble 
material was pelleted by centrifugation (13,000 × g, 10 min, 4°C).  Lysate 
concentrations were determined by BCA assay and equal amounts were incubated 
with GST or GST-PBD beads for 1 h at 4°C.  The beads were pelleted and washed 3 
times in wash buffer (25 mM Tris-HCl pH 7.5, 40 mM NaCl, 30 mM MgCl2, 1% NP-40, 
1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin, leupeptin, and pepstatin A), 
followed by two washes with wash buffer lacking NP-40.  Lysates were subsequently 
prepared for SDS-PAGE, transferred to PVDF membrane and immunoblotted for Rac1 
and GST proteins. 
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Cell spreading assays   
Cells were trypsinized (HyClone), washed three times with phosphate-buffered 
saline (PBS), and resuspended in 0.5% de-lipidated bovine serum albumin (BSA) 
(Sigma) in DMEM for 1 h at 37°C.  Cells were then replated on tissue culture dishes or 
glass coverslips previously coated with collagen IV (10 g/ml) (BD Biosciences).  
Coverslips or tissue cultures dishes were coated with Collagen IV diluted in PBS for 1 
hr at room temperature then washed with PBS and stored at 4°C until ready for use.  
Cells were harvested at the appropriate times for biochemical or microscopic analysis. 
 
Immunofluorescence microscopy   
Cells grown on collagen IV coated coverslips were washed in PBS and fixed in 
4% paraformaldehyde for 10 min at 37°C.  Cells were permeabilized with 0.2% Triton 
X-100 in PBS for 5 min at room temperature.  Coverslips were then washed in PBS 
plus 0.1% Tween 20 (PBST), followed by blocking with 1% BSA in PBST for 30 min.  
Cells were incubated with primary antibodies diluted to 1-3 g/ml in PBST + 1% BSA 
for 1 h at 37°C.  Coverslips were washed 3 x in PBST for 5 min and incubated with 
secondary antibodies diluted to 0.5-2 g/ml in PBST + 1% BSA for 1 h at 37°C.  
Coverslips were washed and mounted on slides with FluorSave Reagent 
(Calbiochem).  Epifluorescence images were captured with a Zeiss Axioskop 
microscope equipped with a Zeiss AxioCam MRm MC100 SPOT digital camera and 
AxioVision software.  For quantitative analysis, images were serially acquired with the 
same illumination and exposure parameters, and the average fluorescence intensity in 
regions of interest for each transfected cell was performed using Image J software.   
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CHAPTER 3:  RESULTS 
Constitutive activation of Rac1 stimulates Net1A activity 
 Net1 activity towards RhoA is inhibited by nuclear sequestration (82, 87).  
Because co-expression of V12Rac1 with Net1A causes its relocalization outside the 
nucleus, we examined whether this also resulted in an increase in the catalytic activity 
of Net1A.  MCF7 breast cancer cells were transfected with expression plasmids for 
HA-Net1, HA-Net1A, or HA-Net1ΔN alone or with Myc-V12Rac1.  After two days the 
cells were harvested and equal amounts of lysate were incubated with recombinant 
GST-RhoA(17A) bound to glutathione-agarose.  GST-RhoA(17A) is a nucleotide-free 
RhoA mutant that binds tightly to active Rho GEFs (121).  After incubation, GST-
RhoA(17A) complexes were pelleted by centrifugation, washed, and resolved by SDS-
PAGE.  The presence of HA-tagged Net1 proteins in these complexes was then 
assessed by Western blotting.  Net1 activity was calculated by dividing the level of 
Net1 in the GST-RhoA(17A) pulldowns by the amount of Net1 in the lysate, normalized 
to the amount of GST-RhoA(17A) used in the pulldown (GST-RhoA(17A) bound Net1 / 
total Net1 in lysate / GST-RhoA(17A) in pulldown). 
As shown in Figure 4, both HA-Net1 and HA-Net1N displayed a high level of 
activity in MCF7 cells irrespective of whether V12Rac1 was co-expressed.  This was 
expected for Net1ΔN, as it has been reported previously to function as a constitutively 
active form of Net1 in other cell types (60, 82).  Similarly, Net1 has been reported to be 
constitutively active (87, 91).  On the other hand, HA-Net1A expressed alone in MCF7 
cells displayed very little activity.  However, co-expression of V12Rac1 strongly 
activated Net1A, increasing its ability to bind to GST-RhoA(17A) by nearly three-fold.  
Interestingly, co-expression of V12Rac1 also increased the expression of each Net1 
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isoform.  Since Net1A has been observed previously to be targeted for proteasome-
mediated degradation (76), this may indicate that co-expression of V12Rac1 stabilizes 
Net1 proteins in general.  In this regard, others in the Frost Lab have observed that co-
expression of V12Rac1 significantly increases the half-life of transfected HA-Net1A 
(data not shown).  Importantly, our method for quantifying Net1 isoform activity 
included normalization for Net1 expression, indicating that increases in Net1A activity 
caused by V12Rac1 co-expression cannot be discounted due to altered Net1A 
expression. Taken together, these data indicate that co-expression of constitutively 
active Rac1 strongly stimulates the activity of Net1A, but not Net1, similar to its effects 
on the extranuclear localization of Net1 isoforms.  
 
Figure 4.  Co-expression of V12Rac1 stimulates Net1A activation.  (A)  Cells were 
transfected with HA-Net1, HA-Net1A, or HA-Net1ΔN, alone or with Myc-
V12Rac1, as indicated.  Equal amounts of lysate from each population of cells 
were incubated with glutathione-agarose-bound GST-RhoA(17A).  Binding of 
Net1 proteins to GST-RhoA(17A) was analyzed by Western blotting (top panel).  
Expression of HA-Net1 proteins and Myc-V12Rac1 in the lysates is shown in the 
bottom panels. Results of a representative experiment are shown.  (B)  
Quantification of Net1 isoform activity.  Active Net1 was defined as the amount 
of HA-Net1 protein in the GST-RhoA(17A) pulldown divided by that in the 
lysate, and values were adjusted according to the amount of GST-RhoA(17A) in 
the pulldowns.  Data were then normalized to the level of activity exhibited to 
HA-Net1 transfected alone.  The results from 6 independent experiments are 
shown.  Significance was determined by Student’s t test for non-paired values.  
* = p < 0.005.   
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Endogenous Rac1 controls Net1A localization 
 When over-expressed alone, approximately 25% of the HA-Net1A transfected 
cells exhibited extranuclear localization of Net1A (Figure 1B).  This begged the 
question of whether endogenous Rac1 activation accounts for the extranuclear 
localization of Net1A in these cells.  To test this idea, MCF7 cells were transfected with 
non-targeting (control) or Rac1-specific siRNAs.  Two days later, the cells were 
transfected with an HA-Net1A expression vector.  Two days after that the cells were 
fixed and stained for HA-Net1A localization.  As shown in Figure 5A, inhibition of Rac1 
expression drastically reduced the extranuclear localization of HA-Net1A.  
Quantification of these results showed that inhibition of Rac1 expression decreased 
the number of cells exhibiting extranuclear localization of Net1A from nearly 30% to 
10%.  These effects were consistent using two siRNAs targeting distinct sequences 
within human Rac1, both of which strongly inhibited Rac1 expression (Figure 5C).  
These data indicate that basal activation of endogenous Rac1 in MCF7 cells drives the 
extranuclear localization of transfected Net1A, and support the notion that Net1A 
relocalization stimulated by exogenously expressed V12Rac1 reflects a valid 
physiological mechanism controlling Net1A localization.   
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Figure 5.  Endogenous Rac1 controls extranuclear localization of Net1A.  Cells 
were transfected with non-targeting control or Rac1-specific siRNAs.  Two days 
later, the cells were re-transfected with an expression vector for HA-Net1A.  
Two days after that, the cells were fixed and stained for HA-Net1A localization.  
(A)  Representative panels showing HA-Net1A localization (green) in control 
and Rac1 siRNA transfected cells.  DNA is stained blue and F-actin is stained 
red.  (B)  Quantification of HA-Net1A localization in control and Rac1 siRNA 
transfected cells.  Shown is the average of three independent experiments.  
Significance was determined by Student’s t test for non-paired values.  * = p < 
0.0002.  (C)  Representative Western blot confirming inhibition of Rac1 
expression. 
 
 
 
Spreading on collagen IV stimulates Rac1 activity and Net1A relocalization 
Our data shows that expression of constitutively active Rac1 causes Net1A 
relocalization outside the nucleus and results in Net1A activation.  Thus, we wanted to 
test whether stimuli that are known to activate endogenous Rac1 also regulated Net1A 
localization in MCF7 cells.  To test this, we examined whether cell spreading after 
trypsinization caused Rac1 dependent Net1A relocalization, since this process is 
known to strongly activate Rac1 in other cells types (110-112).  To determine whether 
replating of MCF7 cells on collagen stimulated endogenous Rac1 activation, actively 
growing cells at 80% confluency were trypsinized and replated on dishes coated with 
collagen IV.  At different times the cells were lysed and tested for Rac1 activation 
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using a conventional pulldown assay (122).  In this assay, cell lysates are incubated 
with the recombinant Rac1 binding domain from Pak1 fused to GST (GST-PBD).  
Since only active Rac1 binds to this domain, the amount of Rac1 bound is directly 
proportional to the degree of Rac1 activation.  Rac1 activation can be detected by 
Western blot, and is quantified by dividing the amount of Rac1 in the pulldowns by the 
amount of Rac1 in the lysate, normalized to the amount of GST-PBD used in the 
pulldown.  In these assays, we observed that endogenous Rac1 was strongly 
activated within 5 min after replating, with peak Rac1 activation occurring within 30 
minutes of replating.  By 90 minutes Rac1 activation had returned to baseline (Figures 
6A and 6B).  Thus, these experiments demonstrate that replating MCF7 cells on 
collagen IV strongly induces endogenous Rac1 activity.   
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Figure 6.  Replating MCF7 cells on collagen strongly activates endogenous 
Rac1.  (A)  Endogenous active Rac1 was pulled down from cell lysates with 
recombinant GST-PBD and analyzed by Western blotting using anti-Rac1 
antibodies.  The upper panel shows Rac1 bound to GST-PBD, the middle panel 
shows Rac1 in the lysate.  GST-PBD in the pulldowns is shown in the lower 
panel.  Shown is a representative experiment.  (B)  Quantification of Rac1 
activation following replating on collagen IV.  Shown is the average of three 
independent experiments.  Significance was determined by Student’s t test for 
non-paired values.  * = p < 0.05. 
 
 
  
We then examined whether replating cells on collagen would stimulate Net1A 
relocalization.  MCF7 cells were transfected with an HA-Net1A expression vector, 
trypsinized, and replated on collagen.  At different times, the cells were then fixed and 
stained for Net1A localization, DNA, and F-actin.  As a positive control, adherent cells 
were co-transfected with V12Rac1.  To more precisely measure HA-Net1A localization, 
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we quantified the fluorescent intensity of HA-Net1A in the nucleus and cytoplasm, and 
displayed the results as a ratio of cytoplasmic to nuclear Net1A (Cyto/Nuc).  Typically, 
nuclear localization of HA-Net1A in MCF7 cells is indicated by a Cyto/Nuc ratio of 
about 0.8, and an increase in this ratio signifies increased localization of Net1A outside 
the nucleus.  By this analysis we observed that HA-Net1A was mainly localized in the 
nucleus in adherent cells before trypsinization and replating, and quickly relocalized 
outside the nucleus upon replating.  Peak relocalization of HA-Net1A outside the 
nucleus occurred 60 min after replating onto collagen, and by 90 min HA-Net1A was 
largely re-localized inside the nucleus (Figures 7A and 7B).  Altogether, these data 
suggest that integrin engagement onto a collagen matrix stimulates Rac1 activation, 
which in turn stimulates Net1A relocalization outside the nucleus.   
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Figure 7.  Relocalization of Net1A in cells spreading on collagen IV.  (A)  Cells 
were transfected with HA-Net1A and then replated on collagen IV coated 
coverslips.  At different times, the cells were fixed and stained for HA-Net1A 
(green), DNA (blue), and F-actin (red).  A representative experiment is shown.  
(B)  Quantification of HA-Net1A subcellular localization.  Fluorescence intensity 
of HA-Net1A staining was analyzed using Image J software and is depicted as 
the ratio of intensities in the cytoplasm and nucleus (Cyto/Nuc).  Shown is the 
average of three independent experiments.  Significance was determined by 
Student’s t test for non-paired values.  * = p < 0.0001.     
 
 
 
Rac1 controls Net1A relocalization during cell spreading 
To determine the role of Rac1 on Net1A relocalization during cell spreading, we 
transfected MCF7 cells with control or Rac1-specific siRNAs.  One day later, the cells 
were re-transfected with an HA-Net1A expression vector.  Two days after that, the 
cells were trypsinized and replated on collagen coated coverslips.  At different times 
the cells were fixed and stained for HA-Net1A localization, DNA, and F-actin.  In these 
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experiments cells depleted of Rac1 exhibited a reduced rate of spreading, consistent 
with a pivotal role for Rac1 in early spreading events in other cell types (108, 111, 
112).  Importantly, we also observed that inhibition of Rac1 expression completely 
inhibited the relocalization of Net1A during cell spreading (Figures 8A and 8B).  These 
data indicate that Rac1 expression is necessary for Net1A relocalization outside the 
nucleus in spreading cells.   
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Figure 8.  Net1A relocalization during cell spreading requires Rac1 expression.  
(A)  Cells were transfected with control or Rac1-specific siRNAs, and then two 
days later re-transfected with HA-Net1A expression vector.  Two days after that, 
the cells were trypsinized and replated on collagen coated coverslips.  At 
different times the cells were fixed and stained for HA-Net1A (green), DNA 
(blue), and F-actin (red).  Shown is a representative experiment.  (B)  
Quantification of HA-Net1A subcellular localization.  The fluorescence intensity 
of HA-Net1A in the cytoplasm and nucleus was quantified.  The average of 
three independent experiments is shown.  Significance was determined by 
Student’s t test for non-paired values.  * = p < 0.05; ** = p < 0.0001.  (C)  
Representative Western blot demonstrating knockdown of Rac1 expression. 
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CHAPTER 4:  DISCUSSION 
 Net1 activity towards RhoA is negatively regulated by nuclear localization (61, 
87).  However, stimuli causing the redistribution of Net1 isoforms outside the nucleus 
have not been published.  In the present study, we have demonstrated that expression 
of constitutively active Rac1 stimulates Net1A re-localization to the plasma membrane 
and results in an up-regulation of Net1A activity.  Interestingly, Net1 appears to 
maintain a high basal activity (Figure 4).  Moreover, Rac1 activation is necessary for 
Net1A relocalization outside the nucleus during cell spreading on a collagen matrix.  
Thus, these data represent the first mechanism for regulating the subcellular 
distribution of Net1A, and demonstrate that the localization of Net1 isoforms is 
differentially regulated.   
 Little is known about mechanisms controlling the nuclear import and export of 
Net1A.  Nuclear import and export are typically regulated by the small GTPase Ran, 
which controls import and export by chaperone proteins known as importins and 
exportins, respectively (98, 99).  We hypothesize that Rac1 activation should alter 
Net1A localization either by negatively regulating Net1A-importin association, up-
regulating Net1A-exportin association, or a combination of the two mechanisms.  
Net1A contains two predicted NLS sequences in its amino-terminus (Figure 2).  Others 
in the Frost Lab have shown that both of these NLS sequences contribute to the 
nuclear localization of Net1A, although the first NLS (NLS3) seems to be the more 
important of the two sequences (not shown).  In this regard, the Frost lab has also 
observed that the importin α subunit, KPNA2, co-immunoprecipitates with Net1A (not 
shown).  In addition, KPNA2 mediates the nuclear import of Rac1 (123).  So 
conceivably, the first NLS (NLS3) of Net1A may bind to KPNA2 to mediate nuclear 
Net1A import.  In this regard it would be important to show whether KPNA2 mediates 
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nuclear import of Net1A, and then to determine whether Rac1 activation alters KPNA2-
dependent Net1A nuclear import. 
It would also be important to determine whether nuclear export mechanisms 
contribute to Rac1 mediated relocalization of Net1A.  Previous work has shown that 
the PH domain of Net1A mediates CRM1 dependent nuclear export of the N-terminal 
truncation mutant, Net1ΔN, from the nucleus (61).  However, others in the Frost Lab 
have observed that treatment of MCF7 cells with the CRM1 inhibitor, leptomycin B, 
does not block nuclear export stimulated by constitutively active Rac1 (not shown).  
Thus, if nuclear export of Net1A contributes to its Rac1 dependent re-localization, then 
one or more exportins other than CRM1 is likely to control this event.  Further work is 
necessary to evaluate how Rac1 activation affects Net1A interaction with the relevant 
importin or exportin. 
The mechanism by which Rac1 signals to cause Net1A relocalization is 
presently not known.  Rac1 initiates intracellular signaling by stimulating the activation 
of a known set of effector proteins.  Thus, identifying the Rac1 effector responsible for 
Net1A relocalization is important to understanding how Net1A localization and activity 
are controlled in breast cancer cells.  There are approximately 30 effectors for Rho, 
Rac, and Cdc42 GTPases (32).  However, since V12Rac1 is more effective than 
constitutively active Cdc42 at causing Net1A relocalization, and RhoA activation does 
not affect Net1A localization (not shown), we would expect that potential effectors 
should be preferentially be activated by Rac1.   
 Rac1-dependent effectors that may be responsible for relocalization of Net1A 
include the kinases MLK2 and 3, MEKK1 and 4, PAKs1-3, the phospholipase PLC-β2, 
and the scaffolding proteins POSH, POR1, p140Sra-1, and IQGAP1-3 (82, 124-134).  
Although this list of effectors is long, the respective function of the possible Rac1 
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effectors can be utilized to identify likely candidates.  For instance, the Rac1 effector 
p70 S6 kinase regulates mRNA translation (32, 135), so it is unlikely to control the 
ability of Net1A to affect actin cytoskeleton organization.  In addition, the Frost lab has 
shown previously that the Rac1/Cdc42 effector PAK1 phosphorylates Net1 in 
response to Rac1 activation, which inhibits its ability to stimulate actin stress fiber 
formation (a RhoA phenotype) (96).  As the PAK1 phosphorylation sites are adjacent 
to the second NLS (NLS4) in Net1A, it is possible that PAK1 mediates Rac1 effects on 
Net1A localization.  Future work will be required to identify the Rac1 effector that 
controls Net1A localization. 
 Because we observed that V12Rac1 expression caused extranuclear 
localization of Net1A, we examined whether stimuli that promote endogenous Rac1 
activation also impact Net1A localization.  For these experiments, we focused on Rac1 
activation stimulated by cellular adhesion, since this is known to require Rac1 at early 
times, followed by RhoA activation at later times (108).  Importantly, we found that cell 
spreading dramatically stimulated the relocalization of Net1A outside the nucleus 
(Figure 7).  Furthermore, we determined that Rac1 was activated by cell spreading in 
MCF7 cells, and that its expression was required for Net1A relocalization (Figures 5 
and 8), Moreover, we also observed that the catalytically-inactive Net1A mutant, 
Net1A L267E, also relocalized outside the nucleus during cell spreading (not shown), 
suggesting that spreading induced Net1A subcellular redistribution independently of 
Net1A-stimulated RhoA activation.  My preliminary data has also suggested that 
Net1A activity is enhanced during cellular spreading, peaking at 60 min following 
adhesion, and returning to basal activity by 90 min (not shown).  Thus, the subcellular 
localization of Net1A is regulated by Rac1 during cell spreading, similar to what we 
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observed in cells transfected with V12Rac1.  This indicates that our over-expression 
experiments are likely to reflect a physiologically relevant regulatory mechanism. 
We then asked whether Net1A re-localization was important for cell spreading.  
Although the results are preliminary, we have observed that MCF7 cells transfected 
with siRNA targeting both Net1 isoforms exhibited a reduced rate of cell spreading in 
comparison to cells treated with control siRNA (not shown), suggesting that Net1A is 
important for efficient cell spreading.  In this regard, the Rho GEFs, LARG, Lsc, and 
p190RhoGEF have been shown to contribute to cell spreading in fibroblasts plated on 
fibronectin and collagen (119, 120).  In the future, it will be important to determine 
whether they also contribute to cell spreading in MCF7 breast cancer cells, and to 
investigate the relationship of Net1A to their function.   
Not surprisingly, the kinetics of Rac1, Net1A, and RhoA activities during 
spreading in MCF7 cells fits with cellular spreading dogma; Rac1 is activated and 
RhoA is down-regulated during early spreading events, and in later spreading stages 
RhoA and Rac1 activities are reversed.  For example, we observed that Rac1 is 
quickly activated by replating on collagen, reaching a peak by 30 min after replating 
(Figure 6).  Moreover, the kinetics of Rac1 activation coincides with the rapid 
relocalization of Net1A outside the nucleus (Figure 7).  Net1A relocalization and 
activity kinetics correlates with peak RhoA activity observed in various cell lines at 30 
to 90 min of spreading on fibronectin and collagen (119, 120, 136, 137).  However, 
RhoA activation in response to Rac1 stimulated Net1A redistribution in MCF7 cells has 
not yet been confirmed by our group. 
Our data are consistent with the following model for Net1A regulation during cell 
spreading.  We have observed that following adhesion to the ECM, cell spreading 
activates Rac1.  Active Rac1 mediates a rapid increase in Net1A nuclear export, or 
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decreased nuclear import.  By unknown mechanisms, extranuclear Net1A maximally 
translocates to the plasma membrane and becomes maximally activated.  
Concurrently, since V12Rac1 co-expression increases the half-life of Net1A (not 
shown), and interaction with the scaffolding protein Dlg1 has been reported to increase 
Net1A stability (76), relocalized Net1A may be stabilized by interaction with Dlg1, 
which typically localizes to the plasma membrane in epithelial cells.  During the latter 
stages of cell spreading, Net1A continues to contribute to RhoA activation, leading to 
efficient focal adhesion and actin stress fiber formation.  Our findings provide a 
physiological role for the Net1A isoform and suggest an added level of control to 
cellular spreading mechanisms, where not only does Rac1 activity antagonize RhoA 
activity following adhesion through Rho GAP activation, but also prepares for RhoA 
activation mediated by temporal and spatial activation of Rho GEFs such as Net1A. 
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CHAPTER 5:  CONCLUSIONS 
  Breast cancer metastasis is the critical event leading to death in breast cancer 
patients.  Understanding the mechanisms controlling metastatic progression of tumor 
cells is thus extremely important, yet this process is not well understood.  It is known 
that activation of Rho family small G proteins, especially RhoA, contributes to breast 
cancer metastasis.  However, there is little data showing how RhoA activation is 
regulated in breast cancer.  Previous work from our lab indicates that Net1 isoforms 
specifically regulate RhoA activity.  It has also been previously established that activity 
of Net1 isoforms are regulated by subcellular localization.  Net1 isoforms are nuclear 
proteins and must be localized outside of the nucleus in order to activate RhoA.  We 
have shown that Rac1 activating stimuli, specifically cellular anchorage to extracellular 
substrates, relocalize Net1A outside the nucleus in a Rac1 dependent manner and 
increase Net1A activity.  These findings suggest that Net1A relocalization may be 
critical for efficient cellular spreading.   
In future research efforts, it would be important to elucidate the mechanisms 
controlling nuclear import and export of Net1A using over-expression, co-
immunoprecipitations, and RNAi approaches.  How Rac1 stimulation alters the nuclear 
import and export dynamics of Net1A should also be studied.  Ways that Rac1 may 
alter Net1A localization may be through increased Net1A export and/or decreased 
importin-Net1A association.  This may occur through Rac1 stimulated post-
translational modification of Net1A, or through altered protein binding to Net1A.  Rac1 
stimulates intracellular signaling by activating a known set of effector proteins.  The 
Rac1 effector that mediates Net1A redistribution could also be identified using a 
combination of RNAi and over-expression methods.  Furthermore, continued 
investigation into the role of Net1A in breast cancer cell spreading is necessary.  It will 
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be interesting to verify if the mechanisms regulating Rac1-induced Net1A 
relocalization in MCF7 cells also contributes to cell spreading in metastatic breast 
cancer cells.  Since cell spreading dynamics are thought to reflect similar mechanisms 
used in cell migration and ECM invasion, Rac1 may also regulate Net1A-dependent 
breast cancer cell migration and invasion.  With this understanding of Net1A 
regulation, novel therapeutic targets can be developed for use in the diagnosis and 
treatment of breast cancer.   
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